Melissa McLaughlin sold $1.3M of ALNY
Chief Human Resources Officer at ALNYLAM PHARMACEUTICALS, INC.. 3,910 shares at an average of $325.92, traded Apr 2, 2026, filed Apr 7, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.3M at market
- +10Share of holdings soldSold 29% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.4%, 3m +0.6%, 6m -29.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178670-26-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -265 | $316.61 | $84k | 13,088 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -359 | $317.44 | $114k | 12,729 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -209 | $318.47 | $67k | 12,520 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -86 | $319.69 | $27k | 12,434 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -147 | $320.62 | $47k | 12,287 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -224 | $321.64 | $72k | 12,063 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -245 | $322.86 | $79k | 11,818 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -81 | $323.64 | $26k | 11,737 | Apr 7, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock10b5-1 | -8 | $325.49 | $2,604 | 11,729 | Apr 7, 2026 |
| Apr 6, 2026 | SOpen-market sale Common Stock10b5-1 | -56 | $320.14 | $18k | 11,673 | Apr 7, 2026 |
| Apr 6, 2026 | SOpen-market sale Common Stock10b5-1 | -909 | $329.76 | $300k | 10,764 | Apr 7, 2026 |
| Apr 6, 2026 | SOpen-market sale Common Stock10b5-1 | -829 | $330.46 | $274k | 9,935 | Apr 7, 2026 |
| Apr 6, 2026 | SOpen-market sale Common Stock10b5-1 | -293 | $331.89 | $97k | 9,642 | Apr 7, 2026 |
| Apr 6, 2026 | SOpen-market sale Common Stock10b5-1 | -199 | $333.94 | $66k | 9,443 | Apr 7, 2026 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 25Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $1.1M 3,830 shares | -71% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 3,250 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.